Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INDVNASDAQ:KRYSNASDAQ:LFSTNASDAQ:PINC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINDVIndivior$13.95-0.4%$11.77$7.33▼$16.69$1.93B0.661.11 million shs1.01 million shsKRYSKrystal Biotech$137.92+4.1%$142.73$122.80▼$219.34$3.83B0.66287,327 shs610,596 shsLFSTLifeStance Health Group$4.96+2.7%$5.92$4.64▼$8.61$1.88B1.231.63 million shs3.26 million shsPINCPremier$21.89-0.8%$21.95$17.23▼$23.56$1.82B0.571.22 million shs1.34 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINDVIndivior0.00%+0.86%+24.42%+38.71%-16.56%KRYSKrystal Biotech0.00%-3.36%+5.93%-31.88%-24.23%LFSTLifeStance Health Group0.00%-8.17%-12.02%-28.55%-8.70%PINCPremier0.00%-2.26%-4.34%+15.56%+18.60%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINDVIndivior3.0383 of 5 stars1.65.00.00.02.31.73.1KRYSKrystal Biotech4.4795 of 5 stars3.51.00.04.72.72.51.9LFSTLifeStance Health Group2.5333 of 5 stars3.42.00.00.02.22.50.6PINCPremier2.1967 of 5 stars1.03.02.50.02.42.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINDVIndivior 3.25Buy$15.007.53% UpsideKRYSKrystal Biotech 3.00Buy$211.1353.08% UpsideLFSTLifeStance Health Group 2.83Moderate Buy$8.5071.37% UpsidePINCPremier 2.00Hold$22.201.42% UpsideCurrent Analyst Ratings BreakdownLatest PINC, INDV, LFST, and KRYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025LFSTLifeStance Health GroupUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$8.505/21/2025PINCPremierPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$19.00 ➝ $24.005/16/2025KRYSKrystal BiotechCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$215.00 ➝ $155.005/15/2025PINCPremierRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$19.00 ➝ $22.005/8/2025PINCPremierCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$19.00 ➝ $22.005/7/2025KRYSKrystal BiotechGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$195.00 ➝ $189.005/7/2025KRYSKrystal BiotechChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$219.00 ➝ $219.005/6/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$240.00 ➝ $240.004/28/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$221.00 ➝ $240.004/8/2025LFSTLifeStance Health GroupKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$9.004/7/2025LFSTLifeStance Health GroupKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINDVIndivior$1.19BN/A$1.81 per share7.70($2.52) per shareN/AKRYSKrystal Biotech$290.52M13.72$4.83 per share28.56$32.90 per share4.19LFSTLifeStance Health Group$1.25B1.54$0.04 per share121.81$3.78 per share1.31PINCPremier$1.35B1.34$3.61 per share6.06$18.68 per share1.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINDVIndivior$2M-$0.31N/A8.16N/A-4.02%-97.29%15.74%7/24/2025 (Estimated)KRYSKrystal Biotech$89.16M$4.1633.1513.68N/A37.17%14.64%13.28%8/4/2025 (Estimated)LFSTLifeStance Health Group-$57.44M-$0.10N/AN/AN/A-2.78%-2.47%-1.69%8/14/2025 (Estimated)PINCPremier$119.54M$0.5738.4016.46N/A5.68%8.79%4.86%8/19/2025 (Estimated)Latest PINC, INDV, LFST, and KRYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025KRYSKrystal Biotech$1.38$1.20-$0.18$1.20$98.66 million$88.18 million4/24/2025Q1 2025INDVIndivior$0.22$0.41+$0.19$0.38$240.13 million$266.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINDVIndiviorN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ALFSTLifeStance Health GroupN/AN/AN/AN/AN/APINCPremier$0.843.84%N/A147.37%N/ALatest PINC, INDV, LFST, and KRYS DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/24/2025PINCPremierquarterly$0.214.2%5/30/20256/1/20256/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINDVIndiviorN/A0.880.72KRYSKrystal BiotechN/A9.659.27LFSTLifeStance Health Group0.191.471.47PINCPremierN/A0.650.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINDVIndivior60.33%KRYSKrystal Biotech86.29%LFSTLifeStance Health Group85.50%PINCPremier74.41%Insider OwnershipCompanyInsider OwnershipINDVIndiviorN/AKRYSKrystal Biotech13.70%LFSTLifeStance Health Group6.60%PINCPremier0.96%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINDVIndivior1,051N/AN/ANot OptionableKRYSKrystal Biotech21028.90 million24.94 millionOptionableLFSTLifeStance Health Group10,218388.88 million363.21 millionOptionablePINCPremier2,90082.34 million81.55 millionOptionablePINC, INDV, LFST, and KRYS HeadlinesRecent News About These CompaniesAero Energy Completes Acquisition of Kraken Energy to Create a Premier North American Uranium DeveloperJune 23 at 8:02 AM | newsfilecorp.comGAMMA Investing LLC Raises Holdings in Premier, Inc. (NASDAQ:PINC)June 20 at 3:13 AM | marketbeat.comExchange Traded Concepts LLC Acquires 16,663 Shares of Premier, Inc. (NASDAQ:PINC)June 18, 2025 | marketbeat.comRitholtz Wealth Management Purchases New Position in Premier, Inc. (NASDAQ:PINC)June 18, 2025 | marketbeat.com1 Small-Cap Stock to Research Further and 2 to Keep Off Your RadarJune 17, 2025 | msn.comPremier, Inc. (NASDAQ:PINC) Shares Sold by Rhumbline AdvisersJune 14, 2025 | marketbeat.comPremier African Minerals shares slump 30% after fresh fundraisingJune 11, 2025 | proactiveinvestors.co.ukOLD National Bancorp IN Makes New $234,000 Investment in Premier, Inc. (NASDAQ:PINC)June 11, 2025 | marketbeat.comHealth-care exec leads 2025 class of CFO of the Year honoreesJune 10, 2025 | bizjournals.comWedge Capital Management L L P NC Boosts Position in Premier, Inc. (NASDAQ:PINC)June 10, 2025 | marketbeat.com42,096 Shares in Premier, Inc. (NASDAQ:PINC) Bought by Two Sigma Investments LPJune 7, 2025 | marketbeat.comPremier, Inc. (NASDAQ:PINC) Director Sells $26,185.11 in StockJune 6, 2025 | insidertrades.comJohn T. Bigalke Sells 1,137 Shares of Premier, Inc. (NASDAQ:PINC) StockJune 5, 2025 | marketbeat.comInsider Selling: Premier, Inc. (NASDAQ:PINC) Director Sells 2,000 Shares of StockJune 3, 2025 | marketbeat.com1 Mooning Stock on Our Buy List and 2 to Be Wary OfJune 3, 2025 | msn.comPremier, Inc. (NASDAQ:PINC) Director Helen M. Boudreau Sells 2,000 SharesJune 3, 2025 | insidertrades.comUniversal Beteiligungs und Servicegesellschaft mbH Makes New $4.29 Million Investment in Premier, Inc. (NASDAQ:PINC)June 2, 2025 | marketbeat.comPremier, Inc. (NASDAQ:PINC) Receives Average Rating of "Hold" from BrokeragesJune 2, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Holdings in Premier, Inc. (NASDAQ:PINC)June 1, 2025 | marketbeat.comNuveen Asset Management LLC Sells 21,079 Shares of Premier, Inc. (NASDAQ:PINC)June 1, 2025 | marketbeat.comPremier American Uranium Positioned for U.S. Nuclear Resurgence Amid Transformational Policy ShiftMay 27, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePINC, INDV, LFST, and KRYS Company DescriptionsIndivior NASDAQ:INDV$13.95 -0.06 (-0.43%) Closing price 04:00 PM EasternExtended Trading$14.02 +0.07 (+0.50%) As of 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Krystal Biotech NASDAQ:KRYS$137.92 +5.46 (+4.12%) Closing price 04:00 PM EasternExtended Trading$135.00 -2.92 (-2.12%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.LifeStance Health Group NASDAQ:LFST$4.96 +0.13 (+2.69%) Closing price 04:00 PM EasternExtended Trading$5.03 +0.07 (+1.31%) As of 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.Premier NASDAQ:PINC$21.89 -0.17 (-0.77%) Closing price 04:00 PM EasternExtended Trading$21.89 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Premier, Inc., together with its subsidiaries, operates as a healthcare improvement company in the United States. It operates in two segments, Supply Chain Services and Performance Services. The Supply Chain Services segment offers its members with an access to a range of products and services, including medical and surgical products, pharmaceuticals, laboratory supplies, capital equipment, information technology, facilities and construction, and food and nutritional products, as well as purchased services, such as clinical engineering and workforce solutions. This segment also provides the ASCENDrive programs for members to receive group purchasing programs, tiers, and prices; SURPASS Performance Group services; and STOCKD, an e-commerce platform, as well as direct sourcing business; SaaS informatics products; supply chain co-management services; purchased services contracts; direct sourcing solutions; and supply chain resiliency programs. The Performance Services segment provides technology and services platform with offerings that help optimize performance in three main areas, including clinical intelligence, margin improvement, and value-based care under the PINC AI brand; third party administrator services and management of health benefit programs under the Contigo Health brand; and digital invoicing and payables services that offers financial support services to healthcare product suppliers and service providers under the Remitra brand. The company was incorporated in 2013 and is based in Charlotte, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
